Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation is a pharmaceutical company focused on research and development for diagnostics and drugs for brain disorders and diseases of the aged, with an emphasis on Alzheimer's disease. The company was incorporated in May 1995 under the Canada Business Corporations Act to acquire DMS Pharmaceutical Inc., which had been conducting research and development since 1989. In 2015, Nymox Pharmaceutical Corporation changed its domicile to The Bahamas. The company funds its operations and projects primarily through the sale of its common stock. Nymox's common shares traded on the Nasdaq Stock Market from December 1, 1996, to July 9, 2023. Shares then traded on the Over the Counter (OTC) Pink Sheets until June 2024, and subsequently began trading on the Over the Counter QB (OCTQB) Venture Market in December 2024, where they have traded since. Nymox's common shares also traded on the Montreal Exchange from December 18, 1995, to November 19, 1999. Since its incorporation in May 1995 through December 31, 2025, Nymox has raised over $204 million by issuing common stock or securities exercisable for common stock. Nymox Pharmaceutical Corporation operates with one wholly-owned subsidiary, Nymox Corporation. Nymox Corporation established an office in California, USA, in August 2018, where it conducts some research and development and manages all Quality Assurance activities for its products. The company's former office in Hasbrouck Heights, New Jersey, has been vacated.